An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma

British Journal of Plastic Surgery

Volumn 53, Issue 1, 2000, Pages 46-50

  Chana, J S ^a   Grover, R ^a   Wilson, G D ^a   Hudson, D A ^b   Forders, M ^b   Sanders, R ^a   Grobbelaar, A O ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acral lentiginous melanoma; p16 tumour suppressor gene; Prognosis; Survival

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; LENTIGO; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0033977650     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjps.1999.3232     Document Type: Article

References (18)

1. Arrington JH III, Reed RJ, Ichinose H, Krementz ET. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol 1977; 1: 131-43.
2. Lehman JA. Acral lentiginous melanoma (see commentary). Plastic Surgery Outlook 1994; 8: 1-2.
3. Muchmore JH, Krementz ET, Reed RJ, Carter RD, Sutherland CM. Melanoma of the hand and foot. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds), Cutaneous Melanoma. 2nd Ed. Philadelphia: Lippincott, 1992; 302-11.
4. Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8,500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds), Cutaneous Melanoma. 2nd Ed. Philadelphia: Lippincott, 1992; 165-87.
5. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8: 23-6.
6. Kamb A, Gruis NA, Weaver Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264(5157): 436-40.
7. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368(6473): 753-6.
8. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366(6456): 704-7.
9. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939-52.
10. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
11. Chana JS, Grover R, Wilson GD, Sanders R. p16 protein expression in benign and malignant melanocytic lesions. Melanoma Res 1997; 7(S1): 28.
12. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
13. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995; 55: 2713-18.
14. Watson JV. Introduction to Flow Cytometry. Cambridge: Cambridge University Press, 1991.
15. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Maelandsmo GM, Florenes VA, Hovig E, et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 1996; 73: 909-16.
17. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996; 56: 5023-32.
18. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p 16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995; 55: 1351-4.